Unit of Hepato-Pancreato-Biliary Surgery and Abdominal Organ Transplantation, Department of Surgery, Doce de Octubre Hospital, Instituto de Investigación, Madrid, Spain.
Faculty of Medicine, Department of Surgery, Complutense University, Madrid, Spain.
Transplantation. 2019 Dec;103(12):2497-2505. doi: 10.1097/TP.0000000000002780.
One method for increasing the donor pool for orthotopic liver transplantations (OLTs) is to use uncontrolled donation after circulation death (uDCDs).
From January 2006 to December 2016, we performed 75 OLTs using uDCD livers. The control group comprised a sample of 265 OLTs using livers of donations after brain death (DBDs). A comparative study was performed.
Of 256 potential uDCD donors cannulated, 75 (29.3%) livers were accepted for OLT. The amount of hemoderivatives transfused was significantly higher in the uDCD group. The rate of primary nonfunction was also significantly higher (P = 0.031) in uDCD recipients (8%) than DBD recipients (1.5%). The overall rate of biliary complications was significantly higher (P = 0.001) in uDCD recipients (23 cases, 30.6%) than DBD recipients (28 cases, 10.6%). In the uDCD group, 1-, 3-, and 5-year patient survival rates were 82.7%, 73%, and 71.5%, respectively; in the DBD group, they were 89%, 83.7%, and 78.8%, respectively (P = 0.180). In the uDCD group, 1-, 3-, and 5-year graft survival rates were 73.3%, 65.1%, and 63.6%, respectively; in the DBD group, they were 87.1%, 81.9%, and 76.5%, respectively (P = 0.013). Multivariate analysis showed that independent risk factors for patient and graft survival were intraoperative transfusion of >6 units of packed red blood cell concentrates and recipients who were older than 60 years.
Although graft survival is significantly lower using uDCD livers, 5-year patient survival in recipients of DBD and uDCD livers is similar. After careful selection, the livers of uDCD can be selectively used for OLT.
增加原位肝移植(OLT)供体库的一种方法是使用无控制的循环死亡后捐献(uDCD)。
自 2006 年 1 月至 2016 年 12 月,我们使用 uDCD 肝脏进行了 75 例 OLT。对照组包括 265 例使用脑死亡供体(DBD)肝脏的 OLT 样本。进行了一项对照研究。
在 256 例潜在的 uDCD 供体中,有 75 例(29.3%)肝脏被接受用于 OLT。uDCD 组输注血液制品的量明显更高。uDCD 受者(8%)原发性无功能的发生率也明显高于 DBD 受者(1.5%)(P = 0.031)。uDCD 受者(23 例,30.6%)的胆道并发症总发生率明显高于 DBD 受者(28 例,10.6%)(P = 0.001)。在 uDCD 组中,1 年、3 年和 5 年患者生存率分别为 82.7%、73%和 71.5%;在 DBD 组中,它们分别为 89%、83.7%和 78.8%(P = 0.180)。在 uDCD 组中,1 年、3 年和 5 年移植物生存率分别为 73.3%、65.1%和 63.6%;在 DBD 组中,它们分别为 87.1%、81.9%和 76.5%(P = 0.013)。多变量分析显示,患者和移植物存活率的独立危险因素是术中输注>6 单位浓缩红细胞和受者年龄>60 岁。
尽管使用 uDCD 肝脏的移植物存活率显著降低,但 DBD 和 uDCD 肝脏受者的 5 年患者存活率相似。经过仔细选择,uDCD 的肝脏可以选择性地用于 OLT。